Microbix Biosystems Inc. (MBX) - Net Assets

Latest as of June 2026: CA$24.26 Million CAD ≈ $17.55 Million USD

Based on the latest financial reports, Microbix Biosystems Inc. (MBX) has net assets worth CA$24.26 Million CAD (≈ $17.55 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$34.06 Million ≈ $24.64 Million USD) and total liabilities (CA$9.80 Million ≈ $7.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Microbix Biosystems Inc. PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Key Net Assets Metrics

Metric Value
Current Net Assets CA$24.26 Million
% of Total Assets 71.23%
Annual Growth Rate 4.55%
5-Year Change 49.75%
10-Year Change 81.72%
Growth Volatility 61.06

Microbix Biosystems Inc. - Net Assets Trend (1997–2025)

This chart illustrates how Microbix Biosystems Inc.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Microbix Biosystems Inc. market cap and net worth.

Annual Net Assets for Microbix Biosystems Inc. (1997–2025)

The table below shows the annual net assets of Microbix Biosystems Inc. from 1997 to 2025. Also explore Microbix Biosystems Inc. (MBX) net asset momentum to track the company's year-over-year net asset growth rate.

Year Net Assets Change
2025-09-30 CA$27.79 Million
≈ $20.10 Million		 -1.80%
2024-09-30 CA$28.30 Million
≈ $20.47 Million		 +14.92%
2023-09-30 CA$24.62 Million
≈ $17.81 Million		 -1.26%
2022-09-30 CA$24.94 Million
≈ $18.04 Million		 +34.40%
2021-09-30 CA$18.56 Million
≈ $13.42 Million		 +180.33%
2020-09-30 CA$6.62 Million
≈ $4.79 Million		 -37.18%
2019-09-30 CA$10.54 Million
≈ $7.62 Million		 +1.78%
2018-09-30 CA$10.35 Million
≈ $7.49 Million		 -31.77%
2017-09-30 CA$15.17 Million
≈ $10.98 Million		 -0.77%
2016-09-30 CA$15.29 Million
≈ $11.06 Million		 +11.81%
2015-09-30 CA$13.68 Million
≈ $9.89 Million		 +38.96%
2014-09-30 CA$9.84 Million
≈ $7.12 Million		 +72.02%
2013-09-30 CA$5.72 Million
≈ $4.14 Million		 +38.74%
2012-09-30 CA$4.12 Million
≈ $2.98 Million		 -19.89%
2011-09-30 CA$5.15 Million
≈ $3.72 Million		 -8.84%
2010-09-30 CA$5.65 Million
≈ $4.09 Million		 -11.93%
2009-09-30 CA$6.41 Million
≈ $4.64 Million		 -15.86%
2008-09-30 CA$7.62 Million
≈ $5.51 Million		 +233.83%
2007-09-30 CA$2.28 Million
≈ $1.65 Million		 +54.41%
2006-09-30 CA$1.48 Million
≈ $1.07 Million		 -46.59%
2005-09-30 CA$2.77 Million
≈ $2.00 Million		 +21.21%
2004-09-30 CA$2.28 Million
≈ $1.65 Million		 +14.89%
2003-09-30 CA$1.99 Million
≈ $1.44 Million		 -6.17%
2002-09-30 CA$2.12 Million
≈ $1.53 Million		 +3.39%
2001-09-30 CA$2.05 Million
≈ $1.48 Million		 +16.19%
2000-09-30 CA$1.76 Million
≈ $1.28 Million		 +3.72%
1999-09-30 CA$1.70 Million
≈ $1.23 Million		 -73.44%
1998-09-30 CA$6.40 Million
≈ $4.63 Million		 -20.00%
1997-09-30 CA$8.00 Million
≈ $5.79 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Microbix Biosystems Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 9009.3% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (September 2025)

Component Amount Percentage
Common Stock CA$50.43 Million 181.49%
Other Comprehensive Income CA$2.27 Million 8.18%
Other Components CA$10.72 Million 38.58%
Total Equity CA$27.79 Million 100.00%

Microbix Biosystems Inc. Competitors by Market Cap

The table below lists competitors of Microbix Biosystems Inc. ranked by their market capitalization.

Company Market Cap
Aurora Mobile Ltd
NASDAQ:JG
 $29.84 Million
China Crystal New Material
KQ:900250
 $29.85 Million
Asuransi Harta Aman Pratama Tbk PT
JK:AHAP
 $29.86 Million
HI SPAC 3
KQ:217500
 $29.86 Million
Etiler İnci Bufe Gida Sanayi ve Dis Ticaret AS
IS:ETILR
 $29.83 Million
Bumi Teknokultura Unggul Tbk
JK:BTEK
 $29.83 Million
E4U a.s.
PR:EFORU
 $29.83 Million
Partnera Oyj
HE:PARTNE1
 $29.82 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Microbix Biosystems Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 28,297,428 to 27,787,542, a change of -509,886 (-1.8%).
  • Net loss of 2,245,812 reduced equity.
  • Share repurchases of 1,730,586 reduced equity.
  • Other factors increased equity by 3,466,512.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CA$-2.25 Million -8.08%
Share Repurchases CA$1.73 Million -6.23%
Other Changes CA$3.47 Million +12.48%
Total Change CA$- -1.80%

Book Value vs Market Value Analysis

This analysis compares Microbix Biosystems Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.50x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has increased from 1.21x to 1.50x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1997-09-30 CA$0.25 CA$0.30 x
1998-09-30 CA$0.18 CA$0.30 x
1999-09-30 CA$0.05 CA$0.30 x
2000-09-30 CA$0.05 CA$0.30 x
2001-09-30 CA$0.06 CA$0.30 x
2002-09-30 CA$0.06 CA$0.30 x
2003-09-30 CA$0.05 CA$0.30 x
2004-09-30 CA$0.07 CA$0.30 x
2005-09-30 CA$0.08 CA$0.30 x
2006-09-30 CA$0.04 CA$0.30 x
2007-09-30 CA$0.06 CA$0.30 x
2008-09-30 CA$0.17 CA$0.30 x
2009-09-30 CA$0.14 CA$0.30 x
2010-09-30 CA$0.12 CA$0.30 x
2011-09-30 CA$0.09 CA$0.30 x
2012-09-30 CA$0.07 CA$0.30 x
2013-09-30 CA$0.09 CA$0.30 x
2014-09-30 CA$0.14 CA$0.30 x
2015-09-30 CA$0.17 CA$0.30 x
2016-09-30 CA$0.18 CA$0.30 x
2017-09-30 CA$0.18 CA$0.30 x
2018-09-30 CA$0.11 CA$0.30 x
2019-09-30 CA$0.11 CA$0.30 x
2020-09-30 CA$0.06 CA$0.30 x
2021-09-30 CA$0.13 CA$0.30 x
2022-09-30 CA$0.18 CA$0.30 x
2023-09-30 CA$0.18 CA$0.30 x
2024-09-30 CA$0.21 CA$0.30 x
2025-09-30 CA$0.20 CA$0.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Microbix Biosystems Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -8.08%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -12.08%
  • • Asset Turnover: 0.50x
  • • Equity Multiplier: 1.35x
  • Recent ROE (-8.08%) is above the historical average (-34.89%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1997 -1.25% -3.70% 0.30x 1.14x CA$-900.00K
1998 -32.81% -67.74% 0.37x 1.31x CA$-2.74 Million
1999 -276.47% -293.75% 0.59x 1.59x CA$-4.87 Million
2000 -25.53% -24.25% 0.64x 1.65x CA$-626.55K
2001 11.77% 8.07% 1.01x 1.44x CA$36.24K
2002 3.28% 2.48% 1.03x 1.28x CA$-142.32K
2003 -18.30% -12.78% 0.96x 1.50x CA$-562.47K
2004 0.62% 0.35% 1.21x 1.48x CA$-214.09K
2005 4.53% 2.87% 1.11x 1.43x CA$-151.27K
2006 -141.50% -57.41% 0.92x 2.68x CA$-2.24 Million
2007 -118.79% -66.98% 0.70x 2.54x CA$-2.94 Million
2008 -48.13% -73.45% 0.34x 1.92x CA$-4.43 Million
2009 -38.75% -40.85% 0.43x 2.20x CA$-3.13 Million
2010 -44.95% -39.28% 0.45x 2.53x CA$-3.10 Million
2011 -50.77% -41.97% 0.45x 2.68x CA$-3.13 Million
2012 -63.94% -39.53% 0.49x 3.28x CA$-3.05 Million
2013 0.02% 0.02% 0.60x 2.22x CA$-570.76K
2014 1.72% 2.01% 0.47x 1.83x CA$-815.22K
2015 4.49% 6.92% 0.38x 1.72x CA$-753.71K
2016 4.89% 7.86% 0.38x 1.65x CA$-780.77K
2017 -24.91% -37.11% 0.39x 1.74x CA$-5.30 Million
2018 -83.27% -68.91% 0.65x 1.87x CA$-9.66 Million
2019 0.30% 0.24% 0.68x 1.86x CA$-1.02 Million
2020 -94.08% -59.17% 0.67x 2.36x CA$-6.89 Million
2021 8.79% 8.77% 0.64x 1.55x CA$-225.43K
2022 7.17% 9.38% 0.58x 1.33x CA$-705.18K
2023 -0.16% -0.24% 0.46x 1.45x CA$-2.50 Million
2024 12.44% 13.86% 0.67x 1.35x CA$690.44K
2025 -8.08% -12.08% 0.50x 1.35x CA$-5.02 Million

Industry Comparison

This section compares Microbix Biosystems Inc.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $8,837,644
  • Average return on equity (ROE) among peers: -298.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Microbix Biosystems Inc. (MBX) CA$24.26 Million -1.25% 0.40x $29.84 Million
Appili Therapeutics Inc (APLI) $4.87 Million -81.69% 0.48x $1.39 Million
Aptose Biosciences Inc (APS) $3.30 Million -97.92% 0.23x $4.43 Million
Arch Biopartners Inc (ARCH) $2.05 Million -52.03% 0.16x $42.26 Million
Biomind Labs Inc (BMND) $-1.43 Million 0.00% 0.00x $38.72 Million
Cybin Inc (CYBN) $86.12 Million -37.41% 0.07x $301.37 Million
Eastwood Bio-Medical Canada Inc (EBM) $-840.80K 0.00% 0.00x $89.55 Million
Eupraxia Pharmaceuticals Inc (EPRX) $-21.66 Million 0.00% 0.00x $438.56 Million
Devonian Health Group Inc (GSD) $52.16K -330.59% 0.68x $17.35 Million
Helix BioPharma Corp. (HBP) $15.76 Million -91.80% 0.15x $80.11 Million
Hemostemix Inc (HEM) $174.08K -2289.23% 3.58x $9.54 Million

About Microbix Biosystems Inc.

TO:MBX Canada Biotechnology
Market Cap
$29.84 Million
CA$41.25 Million CAD
Market Cap Rank
#23902 Global
#894 in Canada
Share Price
CA$0.30
Change (1 day)
-3.23%
52-Week Range
CA$0.21 - CA$0.32
All Time High
CA$0.84
Categories
Companies in Canada Biotechnology
About

Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays… Read more